Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The FDA has approved a transdermal patch for the treatment of early Parkinson's disease. Rotigotine is a non-ergoline, D3/D2/D1 dopamine receptor agonist. It is marketed by Schwarz Bioscience as Neupro.

Rotigotine Transdermal System (Neupro®)